Dr Reddy's and Cipla face US market pressure
Profitability declines continue despite strong product pipeline.
1Decline in the US market
Dr Reddy's and Cipla experienced significant declines in profitability due to the downturn in the US market during the June quarter. Both companies reported double-digit drops in net profit and operating margins.
2Local market performance
Both companies' domestic businesses in India performed well, helping to offset some of the challenges faced in the US. The local market remains a stronghold for these firms.
3Obesity therapies and product launches
Obesity therapies, respiratory products, and biosimilars are emerging as key growth drivers for the upcoming quarters. Cipla has gained early traction in obesity management with Yurpeak, licensed from Eli Lilly.
4Profitability pressures
Operating margins for Dr Reddy's and Cipla have significantly narrowed. Dr Reddy's Ebitda margin dropped to 12.5%, while Cipla's fell to 16.7%, highlighting the profitability challenges both companies face.
5Future expectations
Analysts have reduced earnings forecasts for both companies by 6-8% for the upcoming fiscal years. The stocks of Dr Reddy's and Cipla are expected to remain range-bound in the short term.
6Growth strategies
Despite the challenges in the US market, both companies remain optimistic about the future. New product launches and therapies are central to their long-term growth strategies.
Original article: Economic Times — Dr Reddy's ve Cipla ABD piyasası baskısıyla karşı karşıya